<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933670</url>
  </required_header>
  <id_info>
    <org_study_id>175516</org_study_id>
    <secondary_id>NCI-2018-02195</secondary_id>
    <secondary_id>R01CA211150</secondary_id>
    <secondary_id>R01EB017449</secondary_id>
    <nct_id>NCT03933670</nct_id>
  </id_info>
  <brief_title>Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance</brief_title>
  <official_title>A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) in Patients With Prostate Cancer on Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Biomedical Imaging and Bioengineering (NIBIB)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13&#xD;
      pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer&#xD;
      on active surveillance who have not received treatment. Diagnostic procedures, such as MRI,&#xD;
      may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Optimize the imaging sequences that maximize signal-to-noise ratio (SNR) and intra-tumoral&#xD;
      conversion of HP 13C pyruvate to lactate (kPL) and HP 13C pyruvate to glutamate (kPG) in&#xD;
      regions of tumor versus (vs.) adjacent benign tissue as assessed by multi-parametric MRI&#xD;
      (mpMRI) imaging characteristics. (Part 1) II. Determine the association between intra-tumoral&#xD;
      kPL and kPG with Gleason grade determined during magnetic resonance (MR)/ultrasound&#xD;
      (US)-guided fusion prostate biopsies obtained within 6 months following baseline HP C-13&#xD;
      pyruvate MR exam. (Part 2)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the intra-patient variability in intra-tumoral kPL and kPG with repeated dose&#xD;
      studies.&#xD;
&#xD;
      II. Determine the association between peak intra-tumoral kPL observed on baseline imaging&#xD;
      with serum prostate specific antigen (PSA).&#xD;
&#xD;
      III. Compare and contrast intra-tumoral kPL and kPG with prostate imaging reporting and data&#xD;
      system (PI-RADS) version 2 and individual mpMRI parameters including apparent diffusion&#xD;
      coefficient (ADC) on diffusion-weighted imaging.&#xD;
&#xD;
      IV. Describe the frequency of up-grading of tumor with MR/US-guided fusion biopsy obtained&#xD;
      following baseline HP C-13 MR exam.&#xD;
&#xD;
      V. Further characterize the safety profile of HP C-13 pyruvate injections.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Correlate peak intra-tumoral kPL with results of gene expression profiling using DECIPHER&#xD;
      assay.&#xD;
&#xD;
      II. Correlate peak intra-tumoral kPL and kPG with DECIPHER GRID tumor ribonucleic acid (RNA)&#xD;
      expression of relevant components of the glycolytic pathway including lactate dehydrogenase&#xD;
      (LDH), pyruvate dehydrogenase (PDH), aconitate hydratase (aconitase), myelocytomatosis&#xD;
      oncogene (MYC), monocarboxylate transporter 4 (MCT4) (lactate transporter).&#xD;
&#xD;
      III. For patients who undergo optional follow-up HP C-13 pyruvate/MRI 6-15 months following&#xD;
      baseline scan, determine the mean percent change from baseline in intra-tumoral kPL and kPG&#xD;
      and whether the change from baseline is associated change in clinical risk assessment as&#xD;
      determined by University of California, San Francisco (UCSF)-Cancer of the Prostate Risk&#xD;
      Assessment (CAPRA) risk score.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one&#xD;
      minute, then undergo magnetic resonance spectroscopic imaging (MRSI) after 1-2 minutes.&#xD;
      Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and&#xD;
      undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks&#xD;
      following HP C-13 MRSI.&#xD;
&#xD;
      After completion of study, patients will be followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signal-to-noise ratio (SNR) of hyperpolarized lactate</measure>
    <time_frame>At Baseline</time_frame>
    <description>Assessed by multi-parametric magnetic resonance imaging (mpMRI) characteristics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-tumoral C-pyruvate to lactate (kPL)</measure>
    <time_frame>At Baseline</time_frame>
    <description>Assessed by multi-parametric magnetic resonance imaging (mpMRI) characteristics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-tumoral C-pyruvate to glutamate (kPG)</measure>
    <time_frame>At Baseline</time_frame>
    <description>Assessed by multi-parametric magnetic resonance imaging (mpMRI) characteristics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between intra-tumoral C-pyruvate to lactate (kPL) with Gleason grade</measure>
    <time_frame>Within 12 weeks following baseline HP C-13 pyruvate MR exam</time_frame>
    <description>kPL will be compared with the pathologic Gleason grade determined using tissue from an MR/US-guided fusion prostate biopsy. Measured kPL will be compared by pathologic Gleason grade using an ANOVA model. If there is an overall difference, the Newman-Keuls post hoc test will be used to determine which tissue pairs differ.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between intra-tumoral C-pyruvate to glutamate (kPG) with Gleason grade</measure>
    <time_frame>Within 12 weeks following baseline HP C-13 pyruvate MR exam</time_frame>
    <description>kPG will be compared with the pathologic Gleason grade determined using tissue from an MR/US-guided fusion prostate biopsy. Measured kPG will be compared by pathologic Gleason grade using an ANOVA model. If there is an overall difference, the Newman-Keuls post hoc test will be used to determine which tissue pairs differ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-patient variability in kPL</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Intra-patient variability in the kPL will be summarized by the intraclass correlation and presented with a 90% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-patient variability in kPG</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Intra-patient variability in the kPG will be summarized by the intraclass correlation and presented with a 90% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast between kPL and kPG in regions of tumor</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>The kPL and kPG will be contrasted in regions of tumor. Determined with prostate imaging reporting and data system (PI-RADS) version 2 classification score (1 through 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of kPL and kPG with apparent diffusion coefficient in region of tumor</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>The kPL and kPG will be compared with apparent diffusion coefficient in region of tumor. Determined by comparison to peak intra-tumoral apparent diffusion coefficient (ADC) value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>According to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between peak intra-tumoral kPL observed on baseline imaging with serum PSA</measure>
    <time_frame>At Baseline</time_frame>
    <description>Determine the association between peak intra-tumoral kPL observed on baseline imaging with serum PSA. The study cohort will be dichotomized by mean intra-tumoral kPL above and below the median and the mean serum PSA will be compared between the two dichotomized subgroups using Mann-Whitney test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe frequency of up-grading of tumor</measure>
    <time_frame>Within 12 weeks following baseline HP C-13 pyruvate MR exam</time_frame>
    <description>Describe the frequency of up-grading of tumor with MR/US-guided fusion biopsy obtained following baseline HP C-13 MR exam</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (HP C-13 MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Carbon C 13 Pyruvate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (HP C-13 MRI)</arm_group_label>
    <other_name>Hyperpolarized 13C-Pyruvate</other_name>
    <other_name>Hyperpolarized Pyruvate (13C)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Spectroscopic Imaging</intervention_name>
    <description>Undergo MRSI</description>
    <arm_group_label>Diagnostic (HP C-13 MRI)</arm_group_label>
    <other_name>Hydrogen-1 (1H)- Nuclear Magnetic Resonance Spectroscopic Imaging</other_name>
    <other_name>1H-nuclear magnetic resonance spectroscopic imaging</other_name>
    <other_name>Magnetic Resonance Spectroscopy</other_name>
    <other_name>MRS</other_name>
    <other_name>MRS Imaging</other_name>
    <other_name>MRSI</other_name>
    <other_name>Proton Magnetic Resonance Spectroscopic Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Ultrasound Fusion Guided Biopsy</intervention_name>
    <description>Undergo MR/US fusion-guided prostate biopsy</description>
    <arm_group_label>Diagnostic (HP C-13 MRI)</arm_group_label>
    <other_name>Fusion Biopsy</other_name>
    <other_name>Fusion Guided Biopsy</other_name>
    <other_name>Fusion-Guided Biopsy</other_name>
    <other_name>MR Fusion Biopsy</other_name>
    <other_name>MRI-Ultrasound Fusion Biopsy</other_name>
    <other_name>MRI/Ultrasound Fusion Biopsy</other_name>
    <other_name>MRI/US Biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has biopsy-proven adenocarcinoma of the prostate with low to intermediate&#xD;
             risk disease by UCSF-CAPRA scoring at study entry&#xD;
&#xD;
          -  For Part 1: Patient planning to enroll or currently on active surveillance; For Part&#xD;
             2: Currently enrolled on active surveillance with planned fusion biopsy within 12&#xD;
             weeks following completion of baseline HP C-13 pyruvate/mpMRI on study&#xD;
&#xD;
          -  The subject is able and willing to comply with study procedures and provide signed and&#xD;
             dated informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1000 cells/microliter (uL)&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 gm/deciliter (dL)&#xD;
&#xD;
          -  Platelets &gt;= 75,000 cells/uL&#xD;
&#xD;
          -  Estimated creatinine clearance* &gt;= 50 milliliter (mL)/min&#xD;
&#xD;
               -  by the Cockcroft Gault equation&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) or if =&lt; 3 x ULN if&#xD;
             known/suspected Gilbert's&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) =&lt; 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without evidence of any prostate cancer on most recent prostate biopsy&#xD;
             performed prior to study entry&#xD;
&#xD;
          -  Current or prior androgen deprivation therapy including luteinizing hormone-releasing&#xD;
             hormone (LHRH) analogue or oral anti-androgen therapy. Previous use of a 5-alpha&#xD;
             reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to&#xD;
             baseline C-13 HP pyruvate MRI&#xD;
&#xD;
          -  Prior radiation treatment of the prostate&#xD;
&#xD;
          -  Prostate biopsy performed within 14 days prior to baseline C-13 HP pyruvate MRI&#xD;
&#xD;
          -  Poorly controlled hypertension, with blood pressure at study entry &gt; 160 mm Hg&#xD;
             systolic or &gt; 100 mmg Hg diastolic. Treatment with anti-hypertensives and re-screening&#xD;
             is permitted&#xD;
&#xD;
          -  Contraindication to or inability to tolerate MRI with endorectal coil (e.g. severe&#xD;
             claustrophobia, presence of cardiac pacemaker, aneurysm clip, severe or painful&#xD;
             hemorrhoids, rectal stricture)&#xD;
&#xD;
          -  Congestive heart failure with New York Heart Association (NYHA) status &gt;= 2&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rahul Aggarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khadija Siddiqua</last_name>
    <phone>(310) 794-7329</phone>
    <email>khadija.siddiqua@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khadija Siddiqua</last_name>
      <phone>310-794-7329</phone>
      <email>khadija.siddiqua@ucsf.edu</email>
    </contact>
    <contact_backup>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rahul R. Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Rahul Aggarwal</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

